T. Nishimura

Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy

N. Inui, H. Hashimoto, K. Hori, 2023, JAMA network open.

A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study.

Y. Ohe, Takuhiro Yamaguchi, Y. Uchitomi, 2019, Journal of Clinical Oncology.

Palonosetron exhibits higher total control rate compared to first-generation serotonin antagonists and improves appetite in delayed-phase chemotherapy-induced nausea and vomiting.

H. Yamaue, H. Ueda, C. Shimono, 2014, Molecular and clinical oncology.

A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I.

D. Tsuji, K. Itoh, T. Yokokawa, 2023, Investigational new drugs.